Compare Amphastar Pharmaceuticals Inc (AMPH) vs Lemonade Inc (LMND) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Lemonade (LMND) trades at $70.51, up 0.26% today, with a bullish technical signal from moving averages and strong support at $69. The company shows accelerating revenue growth, with 2025 revenue reaching $738 million, while narrowing net losses to -$166 million. Recent news highlights expansion into new states and reinsurance program improvements, though the stock faces a mixed analyst consensus with 33% buy ratings.

Outlook remains speculative given persistent losses but improving margins; key opportunities include AI-driven growth and market expansion, while risks involve high valuation multiples and profitability timeline uncertainty. The consensus price target of $67 suggests limited near-term upside from current levels.